Amendments to the Claims

1. (Original) A compound of the formula (I):



(I)

wherein

R^1 is hydrogen, halogen, hydroxy, amino, $-CHF_2$, $-CF_3$, or $-NHSO_2CH_3$;

R^2, R^3, and R^4 are each independently selected from the group consisting of:

hydrogen;

halogen;

$-(C_1-C_4)$alkyl;

$-CF_3$;

amino;

nitro;

$-(CH_2)_pOR^{10}$;

$-(CH_2)_nCN$;

$-C(O)NR^{11}R^{12}$;

$-C(O)OR^{16}$;

$-NHC(O)R^{13}$;

$-O(CH_2)_oY$;

$-SCH_3$;

$-SO_2R^{14}$;

N-morpholino;

N-piperazine or N-piperazine substituted with (C_1-C_4)alkyl;

N-pyrrolidine or N-pyrrolidine substituted with $-(CH_2)_pOH$;

N-1,1-dioxothiomorpholine;

N-[1,4]-diazepinyl;

phenyl or phenyl substituted with $-CF_3$, nitro, amino, halogen, hydroxy, (C_1-C_4) alkyl, (C_1-C_4)alkoxy or $-NHSO_2CH_3$; and

piperidine or piperidine substituted on the nitrogen with $-C(O)(C_1-C_4)$ alkyl;

or R^2 and R^3 may, together with the phenyl ring to which they are attached, form a naphthaline (benzo-fused ring) of the structure:



;

R^5, R^6 and R^8 are hydrogen;

R^7 and R^9 are each independently hydrogen or hydroxy;

R^{10} is hydrogen, (C_1-C_4)alkyl, $-(CF_2)_tCHF_2$, $-(CH_2)_qNR^{17}R^{18}$, $-(CH_2)_qO(C_1-C_4$ alkyl), pyrrolidine, or phenyl;

which pyrrolidine may be optionally substituted on the nitrogen with C_1-C_4 alkyl.

R^{11} and R^{12} are each independently hydrogen or (C_1-C_4)alkyl;

R^{13} is (C_1-C_4)alkyl, cyclopropyl or $-(CH_2)-OR^{19}$;

R^{14} is (C_1-C_4)alkyl, $-NR^{20}R^{21}$, N-pyrrolidine, phenyl, or $-CF_3$;

R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, and R^{21} are each independently hydrogen or C_1-C_4 alkyl;

m is 0, 1, 2, or 3;

n is 0 or 1;

o is 1, 2 or 3;

p is 0, 1 or 2;

q is 1, 2, or 3;

t is 0 or 1;

Y is morpholine, pyrrolidine, or pyrrolidine substituted on the nitrogen by (C_1-C_4)alkyl;

and the pharmaceutically acceptable salts thereof.

2. (Original) The compound according to Claim 1, wherein

R^2 is hydrogen, C_1-C_4 alkyl, or phenyl;

R^3 is hydrogen or hydroxy;

R^4 is hydrogen, halogen, nitro, cyano, $-CF_3$, $-(CH_2)_pOR^{10}$, or $-SO_2 R^{14}$;

p is 0;

R^{10} is $-CHF_2$;

R^{14} is (C_1-C_4)alkyl; -CF_3; or –$NR^{20}R^{21}$,
and the pharmaceutically acceptable salts thereof.

3. (Original) The compound according to Claim 2 wherein R^4 is nitro; and the pharmaceutically acceptable salts thereof.

4. (Currently Amended) The compound according to Claim 3 wherein R^2 and R^3 are hydrogen; and the pharmaceutically acceptable salts thereof.

5. (Original) The compound according to Claim 2 wherein R^2 is hydrogen; R^3 is hydroxy; and R^4 is hydrogen; and the pharmaceutically acceptable salts thereof.

6. (Original) The compound according to Claim 1, which is selected from the group consisting of:
7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt;
7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-cyanophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt;
7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(2-methyl-4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt;
(S)-7-Phenyl-isoquinoline-5-sulfonic acid [2-(3-hydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-amide, mesylate salt;
7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-amide isomer 1, dihydrochloride salt; and
7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-amide isomer 2, dihydrochloride salt.

7. (Original) A compound of the formula:



wherein R^1 is hydrogen, halogen, hydroxy, amino, $-CHF_2$ or $-NHSO_2CH_3$;

R^2, R^3, and R^4 are each independently:

hydrogen;

halogen;

-(C1-C4)alkyl;

$-CF_3$;

amino;

nitro;

$-(CH_2)_pOR^{10}$;

$-(CH_2)_nCN$;

$-C(O)NR^{11}R^{12}$;

$-C(O)OR^{11}$;

$-NHC(O)R^{13}$;

$-O(CH_2)_oY$;

$-SCH_3$;

$-SO_2R^{14}$;

N-morpholino;

N-piperazine or N-piperazine substituted with (C1-C4)alkyl;

N-pyrrolidine or N-pyrrolidine substituted with $-(CH_2)_pOH$;

N-1,1-dioxothiomorpholine;

N-[1,4]-diazepinyl;

phenyl or phenyl substituted with $-CF_3$, nitro, amino, halogen, hydroxy, (C1-C4) alkyl, (C1-C4)alkoxy or $-NHSO_2CH_3$;

piperidine or piperidine substituted on the nitrogen with -C(O)(C1-C4) alkyl;

or wherein R^2 and R^3 may together with the phenyl ring of formula I form a naphthaline (benzo-fused ring) of the structure:



;

R^5, R^6 and R^8 are hydrogen;

R^7 and R^9 are each independently hydrogen or hydroxy;

R^{10} is hydrogen, (C1-C4)alkyl, $-(CF_2)_nCHF_2$, $-(CH_2)_mNR^{11}R^{12}$, $-(CH_2)_oO$(C1-C4alkyl), or phenyl;

R^{11} and R^{12} are each independently hydrogen or (C1-C4)alkyl;

R^{13} is (C1-C4)alkyl, cyclopropyl or $-(CH_2)_oR^{11}$;

R^{14} is (C1-C4)alkyl, $-NR^{11}R^{12}$, N-pyrrolidine, phenyl, or $-CF_3$;

m is 0, 1, 2, or 3;

n is 0 or 1;

o is 1, 2 or 3;

p is 0, 1 or 2;

Y is morpholine, pyrrolidine or pyrrolidine substituted on the nitrogen by (C1-C4)alkyl;

and the pharmaceutically acceptable salts thereof.

8. (Original) A compound selected from the group consisting of:

7-phenyl-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-difluoromethylphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-fluorophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-methylsulfonamido)- isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide

7-(3-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide; and

7-(4-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide.

9. (Currently Amended) A pharmaceutical composition comprising a compound of ~~any of Claims 1-7~~Claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

10. (Currently Amended) A method for the treatment of susceptible neoplasms comprising

administering to a patient in need thereof an effective amount of a compound of ~~any of Claims 1-7~~Claim 1, or a pharmaceutically acceptable salt thereof.

11. (Currently Amended) The compound of ~~any of Claims 1-7~~Claim 1, or a pharmaceutically acceptable salt thereof, for use in therapy.